Clinical trial

Safety and Efficacy of Fingolimod in MS Patients in China

NCT01941004

Study summary

ClinicalTrials.gov

Safety and Efficacy of Fingolimod in MS Patients in China

Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record fingolimod Normalized identity: fingolimod View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo (6mos) + open label fingolimod (6 mos) Find medicine records · Find other trials using this name

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2014-06-01

PhasePHASE3

Conditions

Multiple Sclerosis (Relapsing Remitting)unresolved

Interventions

fingolimodDRUG · verified · RxNorm: fingolimod

Placebo (6mos) + open label fingolimod (6 mos)DRUG

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01941004 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.